Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1447016

Emergent BioSolutions Inc. - Product Pipeline Review - Q4 2010

Description:
Emergent BioSolutions Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Emergent BioSolutions Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Emergent BioSolutions Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Emergent BioSolutions Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Emergent BioSolutions Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Emergent BioSolutions Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Emergent BioSolutions Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Emergent BioSolutions Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Emergent BioSolutions Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Emergent BioSolutions Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Emergent BioSolutions Inc. and identify potential opportunities in those areas.
 
Contents:

List of Tables
List of Figures
Emergent BioSolutions Inc. Snapshot
Emergent BioSolutions Inc. Overview
Key Information
Key Facts
Emergent BioSolutions Inc. – Research and Development Overview
Key Therapeutic Areas
Emergent BioSolutions Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Emergent BioSolutions Inc. – Pipeline Products Glance
Emergent BioSolutions Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Emergent BioSolutions Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Emergent BioSolutions Inc. – Drug Profiles
AIG
Product Description
Mechanism of Action
R&D Progress
AV7909
Product Description
Mechanism of Action
R&D Progress
Hepatitis B Therapeutic Vaccine
Product Description
Mechanism of Action
R&D Progress
rPA
Product Description
Mechanism of Action
R&D Progress
Typhella
Product Description
Mechanism of Action
R&D Progress
Advanced Anthrax Vaccines - AV7909 and dmPA7909
Product Description
Mechanism of Action
R&D Progress
AVP-21D9
Product Description
Mechanism of Action
R&D Progress
TRU-016
Product Description
Mechanism of Action
R&D Progress
Chlamydia Vaccine
Product Description
Mechanism of Action
R&D Progress
dmPA7909
Product Description
Mechanism of Action
R&D Progress
MVAH5
Product Description
Mechanism of Action
R&D Progress
Recombinant Botulinum Vaccine
Product Description
Mechanism of Action
R&D Progress
TRU-016
Product Description
Mechanism of Action
R&D Progress
X1 SCORPION Therapeutics
Product Description
Mechanism of Action
R&D Progress
Emergent BioSolutions Inc. – Pipeline Analysis
Emergent BioSolutions Inc. – Pipeline Products by Therapeutic Class
Emergent BioSolutions Inc. Pipeline Products By Target
Emergent BioSolutions Inc. – Pipeline Products by Route of Administration
Emergent BioSolutions Inc. – Pipeline Products by Molecule Type
Emergent BioSolutions Inc. – Recent Pipeline Updates
Emergent BioSolutions Inc. – Company Statement
Emergent BioSolutions Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 09, 2010: Emergent BioSolutions Announces Acceptance Of TRU-016 And TRU-Adhance Abstracts For Presentation At American Society Of Hematology Meeting
Nov 04, 2010: Emergent BioSolutions Receives Orphan Drug Designation For Investigational Monoclonal Antibody For Treatment Of Inhalation Anthrax
Oct 01, 2010: Emergent BioSolutions Receives Fast Track Designation For AVP-21D9 For Treatment Of Inhalational Anthrax
Sep 17, 2010: Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
Sep 08, 2010: Emergent BioSolutions Commences Phase I Clinical Trial For Monoclonal Antibody To Treat Inhalational Anthrax
May 17, 2010: Emergent BioSolutions IND For Anthrax Monoclonal Antibody Therapeutic Clears FDA Review
May 17, 2010: Emergent's IND For Anthrax Monoclonal Antibody Therapeutic Clears FDA Review
Dec 07, 2009: HHS Cancels RFP for rPA Procurement and Modifies Their Approach in Favor of BAA for Development of rPA Vaccines
Sep 30, 2009: NIAID To Fund Development Of Emergent BioSolutions' Advanced Anthrax Vaccine Candidate
Jun 11, 2009: Emergent BioSolutions Meets With FDA To Review Regulatory Strategy For Recombinant Anthrax Vaccine
Financial Deals Landscape
Emergent BioSolutions Inc., Deals Volume Summary, 2004 to YTD 2010
Emergent BioSolutions Inc., Deals Summary By Region, 2004 to YTD 2010
Emergent BioSolutions Inc., Deals Summary, 2004 to YTD 2010
Emergent BioSolutions Inc. Detailed Deal Summary
Asset Purchase
Emergent BioSolutions Acquires Manufacturing Facility From MdBio Foundation
Acquisition
GE Energy Completes Acquisition Of ScanWind From Morphic Technologies And Nord-Trondelag
Andritz Acquires Majority Interest In GEHI From GE Energy
GE Energy Acquires MapFrame
GE Energy Increases Its Equity Interest In PrimeStar Solar
Goldman Sachs And GE Power Invests In Sudhir Gensets
Aggreko completes acquisition of GE Energy Rentals
Aggreko Acquires GE Energy Rentals
Emergent BioSolutions Acquires Vivacs
GE Energy Acquires Altair Filter Technology Group From Gresham Private Equity
Emergent BioSolutions Acquires Microscience
GE Energy Acquires Xin Hua Control Engineering From Shanghai Xinhua Control Technology
GE Energy Acquires BHA Group Holdings
GE Energy Acquires AstroPower
GE Power Systems Acquires Jenbacher
GE Power Systems Acquires Kvaerner Power
GE Energy acquires PII Group
Protein Sciences Terminates Its Acquisition By Emergent BioSolutions
Equity Offering
Emergent Biosolutions Completes Initial Public Offering Of $62.5 Million
Nexterra Energy Enters Into Partnership With GE Energy
Mitsubishi Heavy Industries Partners With GE Energy
Eka Systems Partners With GE Energy
Emergent BioSolutions Forms Joint Venture With The University of Oxford
GE Energy Enters Into Partnership With GAF Materials
Emergent BioSolutions Forms Joint Venture With Ninebio
GE Energy And Bechtel Overseas Power Form Partnership With TransCanada
GE Energy Signs Licensing Agreement With AAER
GE Energy Signs Gasification Licensing Agreement
GE Energy Forms Joint Venture With BP To Develop And Deploy Hydrogen Power Technologies
GE Energy Forms Joint Venture With NPO Saturn
EU Energy Signs Licensing Agreement With GE Energy
GE Energy Signs Licensing Agreement With Repower Systems
GE Energy Partners With Silex Systems
The ERORA Group Signs Licensing Agreement With GE Energy
Encorium Group Enters Into Co-Development Agreement With Emergent BioSolutions
GE Energy Partners With Premier Power
Emergent BioSolutions Partners With Health Protection Agency
Bechtel And Cinergy Partner With GE Energy
GE Energy Forms Partnership With Bechtel
GE Energy Forms Joint Venture With Harbin Power
GE Wind Energy Partners With Airtricity To Develop 25 MW Wind Project In The Irish Sea
Asset Finance
GE Energy Invests $500 Million For Inland Empire CCGT Power Station In California, U.S.
GE Energy To Sell Baglan Bay Gas Fired Power Plant
GE Energy, Stanwell And Xstrata Coal Plans Project Financing For Coal Fired IGCC Power Plant
Licensing Agreements
Emergent BioSolutions Enters Into Licensing Agreement With Pfizer
Xenerex Biosciences Enters Into Licensing Agreement With Emergent Biosolutions
Emergent BioSolutions Enters Into License Agreement With Coley Pharmaceutical
Emergent BioSolutions Enters Into Licensing Agreement With Sanofi Pasteur
Emergent BioSolutions Terminates Licensing Agreement With Sanofi Pasteur
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1447016

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Apr 19th 2014
1:10:48 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Emergent BioSolutions Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1447016

Office Code

OC8DINPPLQSTYY

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 368
Electronic (PDF) - Site License EUR 735
Electronic (PDF) - Enterprisewide EUR 1103

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Apr 19th 2014
1:10:48 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)